Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
208.9 ^USD	+3.18%		+7.47%	-19.27%

Apr. 26	Guggenheim Adjusts Price Target on Biogen to $255 From $275	MT
Apr. 25	Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA	CI

Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application

March 22, 2024 at 08:00 am EDT

March 12, 2024

Biogen to Participate in the Stifel 2024 Virtual CNS Days

Cambridge, MA, - - Biogen Inc (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in a fireside chat during the Stifel 2024 Virtual CNS Days. The webcast will be live on Tuesday, March 19, 2024, at 10:00 a.m. ET.

Attachments

Original Link
Permalink

Disclaimer

Biogen Inc. published this content on 22 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2024 11:59:03 UTC.

Latest news about Biogen Inc.

Guggenheim Adjusts Price Target on Biogen to $255 From $275	Apr. 26	MT
Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA	Apr. 25	CI
Goldman Sachs Adjusts Biogen Price Target to $340 From $393	Apr. 25	MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	Apr. 25	MT
Barclays Adjusts Price Target on Biogen to $200 From $215	Apr. 25	MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325	Apr. 25	MT
Wedbush Adjusts Price Target on Biogen to $215 From $213	Apr. 25	MT
Health Care Down Amid Mixed Earnings -- Health Care Roundup	Apr. 24	DJ
Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 24	MT
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET	Apr. 24	DJ
Wall St edges lower as rising yields overshadow upbeat corporate results	Apr. 24	RE
Morgan Stanley Cuts Biogen's Price Target to $331 From $339	Apr. 24	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Apr. 24	MT
Sector Update: Health Care	Apr. 24	MT
Piper Sandler Raises Biogen's Price Target to $335 From $325	Apr. 24	MT
RBC Lowers Biogen's Price Target to $317 From $326	Apr. 24	MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET	Apr. 24	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 24	DJ
Biogen Affirms Guidance After Mixed First Quarter	Apr. 24	MT
Nasdaq outshines Wall St peers on tech boost, earnings glee	Apr. 24	RE
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 24	DJ
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	Apr. 24	MT
Transcript : Biogen Inc., Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
Biogen's Q1 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Adjusted Earnings Guidance, Shares Gain 4% Pre-Bell	Apr. 24	MT

Chart Biogen Inc.

Duration

Period

More charts

Company Profile

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Sector

Pharmaceuticals

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Biogen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

208.9 USD

Average target price

285.9 USD

Spread / Average Target

+36.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOGEN INC.	-19.27%	30.42B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B
INTRA-CELLULAR THERAPIES, INC.	+2.29%	7.72B

Biopharmaceuticals

Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application

EPS Revisions